Therakos ECP Immunomodulation - Homepage

My Area

Languages:

Therakos e-learning platform

WELCOME TO
THE HOME OF ECP

DISCOVER MORE ABOUT THE PIONEERS OF ECP IMMUNOMODULATION

DISCOVER OUR FULL EDUCATIONAL OFFER INCLUDING
CENTRES OF EXCELLENCE, WEBINARS, SPEAKER MEETINGS AND MORE

REGISTER NOW

GET ACCESS TO THE THERAKOS INSTITUTE, E-LEARNING PLATFORM AND MYTHERAKOS TO KEEP UP TO DATE WITH THERAKOS ECP IMMUNOMODULATION^TM

EIA 2021

THE MALLINCKRODT 2021 ADVANCING ECP IMMUNOMODULATION INVESTIGATOR AWARD

APPLY NOW FOR AN OPPORTUNITY TO OBTAIN A € 50,000 RESEARCH GRANT
TERMS AND CONDITIONS APPLY

The Therakos Institute

Introducing

The Therakos Institute

Read more

20 January 2021

Combinational Therapies in GvHD

Hosted by

Professor Robert Zeiser

Discover

Our Upcoming
Webinars

Register Here

Take a look at

Our On Demand Webinars

See More

21 October 2020

Current and potential use of ECP Immunomodulation in treating Heart Transplant Patients

19 November, 2019

Management of Chronic GvHD: Survivorship & Quality of Life after HSCT and Supportive Care

Upcoming

Events

Discover More

DISCOVER OUR
CELLEX^TM SYSTEM

The world’s only fully integrated and validated ECP system

Discover More

OUR
LEGACY

We are the pioneers of ECP, and have been for over 30 years. Find out what this means for you.

Discover More

HEALTHCARE
PROFESSIONALS

Find out about our full range of services tailored to you.

Discover More

PATIENTS AND
CAREGIVERS

Discover more about extracorporeal photopheresis and see our patient support materials.

Discover More

Upcoming Congresses

European Respiratory Society

September 7-9, 2020

ERS International Congress 2020 – virtual event

Read more

Autoimmune Diseases Working Party

September 24-25, 2020

ADWP Educational Meeting - virtual event

Read more

12th Nurses International Study Day & 4th Nurses Research Day

October 8-9, 2020

12th Nurses International Study Day & 4th Nurses Research Day - virtual event

Read more

5th EBMT International Transplant Course

November 4-6, 2020

5th EBMT International Transplant Course – virtual event

Read more

European Organisation for
Research and Treatment of Cancer

June 17-19, 2021

Marseille

EORTC CLTF - 2021

Read more

Important Safety Information
For the Therakos^TM Photopheresis
Procedure Indications

The THERAKOS^TM UVAR XTS^TM and THERAKOS^TM CELLEX^TM Photopheresis Systems are indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Indications

The THERAKOS^TM UVAR XTS^TM and THERAKOS^TM CELLEX^TM Photopheresis Systems are indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOS^TM Photopheresis is contraindicated in patients possessing a specific history of a light-sensitive disease. THERAKOS^TM Photopheresis is contraindicated in patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 mm³. THERAKOS^TM Photopheresis is contraindicated in patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOS^TM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Both men and women should take adequate contraceptive precautions both during and after completion of photopheresis therapy. Safety in children has not been established.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.

Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated, leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.

Treatment frequency exceeding labelling recommendations may result in anaemia.

Venous access carries a small risk of infection and pain.

When prescribing and administering THERAKOS^TM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

To report an adverse event please contact us at:
INTERNATIONAL FREEPHONE: 00800 84372567 (Available from most countries in Europe and Middle East and Africa)

ecphelp@therakos.com

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients. Methoxsalen is contraindicated in patients with co-existing melanoma, basal cell or squamous cell skin carcinoma. Methoxsalen is contraindicated in sexually active men and women of childbearing potential unless adequate contraception is used during treatment, and during pregnancy and lactation. Methoxsalen is contraindicated in patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens.

Warnings and Precautions

Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitising agents. Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic. Because the dose with liquid methoxsalen is about 200 times less than with PUVA therapy and the skin is not exposed to high cumulative doses of UVA light, the risk of developing skin cancer following this therapy may be lower. Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window. Safety in children has not been established. Refer to the Methoxsalen (20 micrograms/mL) labelling or the oral 8-methoxypsoralen dosage formulation package insert for more information on protecting the patient from light and a list of all warnings and precautions.